Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Equity Income (2022 - 2024)

Amphastar Pharmaceuticals has reported Equity Income over the past 3 years, most recently at -$573000.0 for Q1 2024.

  • For Q1 2024, Equity Income rose 27.01% year-over-year to -$573000.0; the TTM value through Dec 2024 reached -$573000.0, up 71.08%, while the annual FY2024 figure was -$573000.0, 71.08% up from the prior year.
  • Equity Income for Q1 2024 was -$573000.0 at Amphastar Pharmaceuticals, down from -$505000.0 in the prior quarter.
  • Over five years, Equity Income peaked at -$57000.0 in Q4 2022 and troughed at -$785000.0 in Q1 2023.
  • A 3-year average of -$414555.6 and a median of -$390000.0 in 2023 define the central range for Equity Income.
  • Biggest five-year swings in Equity Income: plummeted 785.96% in 2023 and later rose 27.01% in 2024.
  • Year by year, Equity Income stood at -$57000.0 in 2022, then plummeted by 785.96% to -$505000.0 in 2023, then dropped by 13.47% to -$573000.0 in 2024.
  • Business Quant data shows Equity Income for AMPH at -$573000.0 in Q1 2024, -$505000.0 in Q4 2023, and -$390000.0 in Q3 2023.